Entities / Company
Hoffmann-La Roche.
Swiss healthcare company
- Reports this week
- 7
- Active events
- 9
- Connections
- 938
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
CEO Jack Roche emphasized portfolio and partnerships.Some support1 report1 development inside
-
Roche Pharma Vietnam partners with the Bright Future Fund, which is led by Nguyen Thi Xuyen.Some support1 report
-
Hoffmann-La Roche and Danaher are partnering with Nvidia to develop AI-driven labs for R&D and advance autonomous science.Some support1 report
-
Hoffmann-La Roche sponsored a randomized trial involving Adagene's drug on October 17, 2026.Some support1 report
-
Companies are pouring billions into protein degraders, a drug class that has received FDA approval and is being discussed by ASCO.Some support1 report
-
Roche secured exclusive rights to Rona Therapeutics' therapy.Some support1 report
-
Major pharmaceutical companies face safety questions and intense competition in the obesity drug market.Some support1 report
-
Sanofi, Hoffmann-La Roche, Gilead, and Pfizer announced a collaboration to co-develop bexobrutideg, with Sanofi providing a $10M milestone payment.Some support1 report
-
A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.Some support1 report2 developments inside
Earlier this month
-
Roche terminated Ionis's Huntington's drug program, leading to market scrutiny and investment decisions for all involved pharmaceutical companies.Some support1 report
-
Roche, a representative of Hoffmann-La Roche, has been appointed as a city commissioner in Cambridge.Some support1 report
-
Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Well supported6 reports2 developments inside
-
Natera's Signatera test is being used in the AFT-70 NAVIGATE trial, which is co-funded and collaborated on by Genentech.Some support1 report
-
MPP has taken on the management of a voluntary licensing agreement, and Fidson Healthcare Plc has been selected to manufacture a generic antiviral.Some support3 reports
-
Hoffmann-La Roche opened a new R&D center in Boston.Some support3 reports1 development inside
-
Nvidia and Hoffmann-La Roche share interest in AI-driven therapeutics following the establishment of a new innovation center in Boston.Some support1 report
-
Merck, a New Jersey-based drugmaker, was the subject of an RBC Capital Markets analysis regarding its drug showing non-inferiority to a competitor's product from Hoffmann-La Roche.Some support1 report
-
Earendil Labs collaborates with Genentech.Some support1 report
-
Hoffmann-La Roche and Novo Nordisk are competing in the global obesity drug market, with stock trading occurring in Zurich.Some support1 report1 development inside
-
Roche reported positive results from enicepatide trials, showing it reduces HbA1c and weight in Type 2 diabetes.Some support1 report
-
LVMH and Hermes contribute to the global luxury goods market, while Hoffmann-La Roche and Novartis compete in the global pharmaceutical sector.Some support1 report
-
Arvinas secured capital via a Genentech partnership, AdvanCell appointed a new CFO, and Johanna Mylet served as an audit manager.Some support1 report
-
China's rise in vitamin production is putting pressure on European companies, highlighted by the divestment of Roche's vitamins division.Some support2 reports
One to three months ago
-
A company involving Hoffmann-La Roche is facing imminent closure and 100 redundancies amid efforts to secure a new industry.Some support1 report
-
The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.Some support1 report
-
Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.Some support2 reports4 developments inside
-
International agency reports cancer statistics in the Philippines, with MSD and Roche supporting an advocacy summit.Some support2 reports
-
Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.Well supported6 reports1 development inside
-
The FDA has delayed potential approval of a cancer treatment that utilizes Exelixis in combination with Roche's Tecentriq.Some support1 report
-
Major pharmaceutical companies, including Novartis, Roche, AstraZeneca, and Pfizer, maintain significant presences in Switzerland.Some support2 reports2 developments inside
-
Hoffmann-La Roche, the company, has historical ties to Basel, including the fact that Ballmer worked there in 1926.Some support1 report
-
BioNTech is listed on Nasdaq and is advancing pancreatic cancer trials using Roche's Tecentriq, while also partnering with Genentech.Some support2 reports
-
Genentech collaboration supports Duality Biotherapeutics' DUPAC platform confidence.Some support1 report
-
The FDA granted clearance for a Genotek kit, which is used in conjunction with Hoffmann-La Roche molecular testing.Well supported10 reports1 development inside
-
The FDA granted use authorizations for the OraSure kit used in conjunction with Hoffmann-La Roche molecular testing.Some support2 reports
-
Hoffmann-La Roche collaborates with Singaporean institutions, including NUS and NRF, on genomic profiling research to accelerate precision medicine.Some support1 report
-
Silicon Valley ethos influences corporate culture, exemplified by Marc Tessier-Lavigne's research at Hoffmann-La Roche.Some support1 report
-
A Swiss company bought operations for $1.2 billion, leading to expanding operations into Solano County and affecting county employment.Some support1 report
-
Hoffmann-La Roche is building a facility in Holly Springs, North Carolina.Some support2 reports
-
BioNTech pulled the plug on the Phase 2 clinical trial involving Hoffmann-La Roche.Some support1 report
-
Hoffmann-La Roche and DualityBio announced a partnership to develop cancer therapeutics, with John Zhu leading DualityBio.Some support1 report
-
EirGenix and Formosa Pharmaceuticals co-develop a biosimilar candidate, TSY-110, which is an alternative to Kadcyla®.Some support1 report
-
Hoffmann-La Roche, AstraZeneca, and Pfizer are participating in local pharmaceutical production projects in Kazakhstan.Some support1 report
-
Novartis and Hoffmann-La Roche sent campaign contributions to Democrats.Some support1 report
-
Hanmi Pharmaceutical, a South Korean company, successfully licensed one of its obesity drug candidates to the multinational giant Hoffmann-La Roche on August 1, 2026.Some support1 report
-
Easing worries about Middle East tensions involving Hoffmann-La Roche.Some support1 report
-
Roche, Novo Nordisk, and Bristol-Myers Squibb are evaluating new drug candidates for Parkinson's, ATTR amyloidosis, and Alzheimer's diseases.Some support1 report1 development inside
-
Dannielle Appelhans began her career at McKinsey & Company, gained experience, held senior roles, and led a strategic collaboration involving Eli Lilly and Company, Novartis, and Hoffmann-La Roche.Some support1 report
-
Major pharmaceutical companies, including Hoffmann-La Roche and Novartis, are building large production facilities in North Carolina.Some support1 report1 development inside
-
Hoffmann-La Roche entered into a collaboration with an unnamed biopharma company, generating royalty revenue driven by cost reimbursement.Some support1 report1 development inside
-
Hoffmann-La Roche is expected to increase contract manufacturing revenue, including a $40 million milestone payment.Some support1 report
-
The Vanguard International High Dividend Yield ETF holds top positions in companies including Hoffmann-La Roche, HSBC, Novartis, Royal Bank of Canada, and Nestlé, with weak dollar impacting distribution.Some support1 report
-
Nvidia, Eli Lilly, Bristol-Myers Squibb, and Hoffmann-La Roche announced a partnership to build a hybrid-cloud AI factory and powerful AI infrastructure.Some support1 report
-
Lineage's OpRegen RPE cell therapy program was licensed by Roche and Genentech.Some support2 reports
-
Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.Some support2 reports1 development inside
-
Halozyme tracks patient usage of OCREVUS ZUNOVO and monitors Opdivo Qvantig sales and conversion rates.Some support1 report
-
Threats of tariffs and restrictive pricing policies involving major companies like Johnson & Johnson, Eli Lilly, and Roche, alongside Congressional planning.Some support4 reports3 developments inside
-
Denali and Hoffmann-La Roche announced the development of new therapies for Parkinson's disease.Some support1 report
-
Hoffmann-La Roche and Cumberland Pharmaceuticals Inc. are being compared for investment.Some support1 report
-
Roche commercialized a treatment after partnering with Sarepta, while Sarepta simultaneously faced a regulatory pause in the U.S.Some support2 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Hoffmann-La Roche
Events traced to Hoffmann-La Roche, step by step, newest firstAround Hoffmann-La Roche this week
News at the entities that move Hoffmann-La Roche most-
FDA StructuralThe FDA approved GSK's Jemperli drug, while Memorial Sloan Kettering Cancer Center was involved in the AZUR-1 trial.Moves Hoffmann-La Roche
-
Food and Drug Administration StructuralFDA conducted a search operation in Pune on January 1, 2026.Moves Hoffmann-La Roche
-
Halozyme Therapeutics StructuralCorcept Therapeutics and Halozyme Therapeutics are identified as top holdings in specific U.S. small-cap ETFs.Moves Hoffmann-La Roche
-
Pfizer OperationalStudy results were presented by Tempus and Pfizer at the ESMO Congress, focusing on ongoing collaboration regarding diagnostic barriers.Moves Hoffmann-La Roche
-
Eli Lilly and Company OperationalEli Lilly and Company announced a $4.5 billion investment in its facilities located in Indiana.Moves Hoffmann-La Roche
-
Recursion (United States) StructuralRecursion Pharmaceuticals announced strategic alliances with Bayer, Sanofi, Roche, Merck, and Genentech.Moves Hoffmann-La Roche
Connections
The 40 strongest of 938, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Halozyme Therapeutics Structural
Roche utilizes Halozyme's ENHANZE drug delivery technology under a licensing agreement, generating royalty payments.
-
Recursion (United States) Structural
The relationship is a critical, ongoing strategic partnership focused on joint drug discovery, generating mutual revenue and candidates.
-
Pfizer Operational
Pfizer and Hoffmann-La Roche are key competitors in specialized pharmaceutical markets, including Danon Disease and GLP-1 drug development.
-
Novo Nordisk Operational
Hoffmann-La Roche and Novo Nordisk are direct competitors in the global obesity and weight-loss drug markets.
-
FDA Structural
The FDA formally regulates Hoffmann-La Roche's pharmaceutical products, granting approvals and tracking safety for market access.
-
Alnylam Pharmaceuticals Operational
Alnylam and Roche maintain an ongoing operational partnership involving joint drug development and milestone payments.
-
LabCorp Structural
LabCorp utilizes companion diagnostic tests provided by Hoffmann-La Roche for prostate cancer testing.
-
Novartis Transactional
Novartis completed the divestiture by selling its investment stake in Hoffmann-La Roche.
Show all 40 connections
-
National Cancer Centre Singapore Structural
The partnership between Roche and the National Cancer Centre Singapore is focused on leveraging combined expertise to accelerate precision medicine research.
-
Paulo Fontoura Structural
Paulo Fontoura was employed by Hoffmann-La Roche for 15 years.
-
Eli Lilly and Company Operational
Hoffmann-La Roche and Eli Lilly and Company are actively collaborating on product development, securing joint market authorizations, and participating in test launches.
-
Merck Operational
Roche and Merck are direct competitors in the immuno-oncology and PD-L1 inhibitor markets.
-
Lineage Cell Therapeutics Operational
Hoffmann-La Roche and Lineage Cell Therapeutics maintain an exclusive worldwide collaboration for the development and optimization of the OpRegen therapy.
-
Sarepta Therapeutics Operational
Sarepta Therapeutics and Hoffmann-La Roche are actively collaborating on the development and contract manufacturing of the Elevidys gene therapy.
-
Herbert Boyer Structural
Hoffmann-La Roche's current research and products are founded upon the specific DNA cutting research conducted by Herbert Boyer.
-
Basilea Pharmaceutica Structural
Basilea Pharmaceutica was established as a spin-off from Hoffmann-La Roche.
-
Exelixis Operational
Exelixis utilizes Roche's Tecentriq product as part of a combined therapeutic approach.
-
AstraZeneca Operational
Hoffmann-La Roche and AstraZeneca are direct competitors in the pharmaceutical market, facing shared market pressures and rivalry in drug development.
-
Medicines Patent Pool Structural
The Medicines Patent Pool holds a voluntary licensing agreement with Hoffmann-La Roche.
-
Nvidia Operational
The entities maintain an active operational collaboration focused on developing AI-driven therapeutics and biotech.
-
TTR Transactional
Hoffmann-La Roche is currently evaluating TTR's technology/product, prasinezumab, for potential application in Parkinson's disease.
-
University of California Structural
Hoffmann-La Roche was founded based on research conducted at the University of California.
-
Hanmi Pharmaceutical Structural
Hanmi Pharmaceutical holds a licensing agreement with Roche Group for its obesity drug.
-
Biogen Structural
Biogen receives royalties from drugs developed by Hoffmann-La Roche.
-
JAMA Structural
Hoffmann-La Roche utilizes JAMA as a peer-reviewed platform for publishing studies that support its test development.
-
Johnson & Johnson Operational
Roche and Johnson & Johnson are actively competing in the oncology and generalized myasthenia gravis markets.
-
Astex Pharmaceuticals Transactional
Exclusive license granted for breast cancer compounds.
-
Sarawak General Hospital Operational
SGH provides testing services and samples to Hoffmann-La Roche for drug development.
-
Food and Drug Administration Structural
The FDA formally cleared Roche's blood test for Alzheimer's, establishing a regulatory dependency.
-
Genotek Structural
Genotek provides kits that are utilized by Hoffmann-La Roche for molecular testing.
-
Nigeria Operational
The operational environment of the pharmaceutical supply chain is compromised by the infiltration of counterfeit drugs, affecting both the national market in Nigeria and the global industry standards upheld by Hoffmann-La Roche.
-
GSK Operational
The two companies are actively competing in the market, specifically regarding lung cancer treatments.
-
Kazakhstan Structural
Hoffmann-La Roche maintains a functional presence in Kazakhstan through ongoing local production projects.
-
Bristol-Myers Squibb Operational
Both companies are direct competitors in the pharmaceutical market, offering drugs for lung cancer and facing comparative market pressures.
-
Allston Structural
Hoffmann-La Roche is establishing a research hub in Allston.
-
OraSure Technologies Structural
OraSure supplies testing kits that are utilized by Hoffmann-La Roche for its procedures.
-
MoSS Operational
The relationship is currently operational, involving A leveraging B's work to increase contract manufacturing revenue.
-
Boston Structural
Hoffmann-La Roche is establishing a functional and ongoing R&D presence within the city of Boston.
-
Ionis Pharmaceuticals Transactional
Roche terminated the drug development partnership it held with Ionis Pharmaceuticals.
-
Ivana Structural
Ivana gained professional experience while employed at Hoffmann-La Roche.
History
Events by the month they beganOctober 2026
11 events- Roche Pharma Vietnam partners with the Bright Future Fund, which is led by Nguyen Thi Xuyen.
- Hoffmann-La Roche and Danaher are partnering with Nvidia to develop AI-driven labs for R&D and advance autonomous science.
- Hoffmann-La Roche sponsored a randomized trial involving Adagene's drug on October 17, 2026.
- Companies are pouring billions into protein degraders, a drug class that has received FDA approval and is being discussed by ASCO.
- Roche secured exclusive rights to Rona Therapeutics' therapy.
- Major pharmaceutical companies face safety questions and intense competition in the obesity drug market.
- Sanofi, Hoffmann-La Roche, Gilead, and Pfizer announced a collaboration to co-develop bexobrutideg, with Sanofi providing a $10M milestone payment.
- Roche terminated Ionis's Huntington's drug program, leading to market scrutiny and investment decisions for all involved pharmaceutical companies.
- Roche, a representative of Hoffmann-La Roche, has been appointed as a city commissioner in Cambridge.
- Natera's Signatera test is being used in the AFT-70 NAVIGATE trial, which is co-funded and collaborated on by Genentech.
- MPP has taken on the management of a voluntary licensing agreement, and Fidson Healthcare Plc has been selected to manufacture a generic antiviral.
September 2026
17 events- Hoffmann-La Roche opened a new R&D center in Boston.
- Nvidia and Hoffmann-La Roche share interest in AI-driven therapeutics following the establishment of a new innovation center in Boston.
- Merck, a New Jersey-based drugmaker, was the subject of an RBC Capital Markets analysis regarding its drug showing non-inferiority to a competitor's product from Hoffmann-La Roche.
- Earendil Labs collaborates with Genentech.
- Hoffmann-La Roche and Novo Nordisk are competing in the global obesity drug market, with stock trading occurring in Zurich.
- Roche reported positive results from enicepatide trials, showing it reduces HbA1c and weight in Type 2 diabetes.
- LVMH and Hermes contribute to the global luxury goods market, while Hoffmann-La Roche and Novartis compete in the global pharmaceutical sector.
- Arvinas secured capital via a Genentech partnership, AdvanCell appointed a new CFO, and Johanna Mylet served as an audit manager.
- China's rise in vitamin production is putting pressure on European companies, highlighted by the divestment of Roche's vitamins division.
- A company involving Hoffmann-La Roche is facing imminent closure and 100 redundancies amid efforts to secure a new industry.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- International agency reports cancer statistics in the Philippines, with MSD and Roche supporting an advocacy summit.
- The FDA has delayed potential approval of a cancer treatment that utilizes Exelixis in combination with Roche's Tecentriq.
- Hoffmann-La Roche, the company, has historical ties to Basel, including the fact that Ballmer worked there in 1926.
- BioNTech is listed on Nasdaq and is advancing pancreatic cancer trials using Roche's Tecentriq, while also partnering with Genentech.
- Genentech collaboration supports Duality Biotherapeutics' DUPAC platform confidence.
- The FDA granted use authorizations for the OraSure kit used in conjunction with Hoffmann-La Roche molecular testing.
August 2026
20 events- Hoffmann-La Roche collaborates with Singaporean institutions, including NUS and NRF, on genomic profiling research to accelerate precision medicine.
- Silicon Valley ethos influences corporate culture, exemplified by Marc Tessier-Lavigne's research at Hoffmann-La Roche.
- A Swiss company bought operations for $1.2 billion, leading to expanding operations into Solano County and affecting county employment.
- Hoffmann-La Roche is building a facility in Holly Springs, North Carolina.
- BioNTech pulled the plug on the Phase 2 clinical trial involving Hoffmann-La Roche.
- Hoffmann-La Roche and DualityBio announced a partnership to develop cancer therapeutics, with John Zhu leading DualityBio.
- EirGenix and Formosa Pharmaceuticals co-develop a biosimilar candidate, TSY-110, which is an alternative to Kadcyla®.
- Hoffmann-La Roche, AstraZeneca, and Pfizer are participating in local pharmaceutical production projects in Kazakhstan.
- Novartis and Hoffmann-La Roche sent campaign contributions to Democrats.
- Hanmi Pharmaceutical, a South Korean company, successfully licensed one of its obesity drug candidates to the multinational giant Hoffmann-La Roche on August 1, 2026.
- Easing worries about Middle East tensions involving Hoffmann-La Roche.
- Roche, Novo Nordisk, and Bristol-Myers Squibb are evaluating new drug candidates for Parkinson's, ATTR amyloidosis, and Alzheimer's diseases.
- Dannielle Appelhans began her career at McKinsey & Company, gained experience, held senior roles, and led a strategic collaboration involving Eli Lilly and Company, Novartis, and Hoffmann-La Roche.
- Major pharmaceutical companies, including Hoffmann-La Roche and Novartis, are building large production facilities in North Carolina.
- Hoffmann-La Roche is expected to increase contract manufacturing revenue, including a $40 million milestone payment.
- The Vanguard International High Dividend Yield ETF holds top positions in companies including Hoffmann-La Roche, HSBC, Novartis, Royal Bank of Canada, and Nestlé, with weak dollar impacting distribution.
- Nvidia, Eli Lilly, Bristol-Myers Squibb, and Hoffmann-La Roche announced a partnership to build a hybrid-cloud AI factory and powerful AI infrastructure.
- Halozyme tracks patient usage of OCREVUS ZUNOVO and monitors Opdivo Qvantig sales and conversion rates.
- Denali and Hoffmann-La Roche announced the development of new therapies for Parkinson's disease.
- Hoffmann-La Roche and Cumberland Pharmaceuticals Inc. are being compared for investment.
Show 2 earlier months
July 2026
1 eventJune 2026
11 events- CEO Jack Roche emphasized portfolio and partnerships.
- A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.
- Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.
- Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.
- Major pharmaceutical companies, including Novartis, Roche, AstraZeneca, and Pfizer, maintain significant presences in Switzerland.
- The FDA granted clearance for a Genotek kit, which is used in conjunction with Hoffmann-La Roche molecular testing.
- Lineage's OpRegen RPE cell therapy program was licensed by Roche and Genentech.
- Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.
- Threats of tariffs and restrictive pricing policies involving major companies like Johnson & Johnson, Eli Lilly, and Roche, alongside Congressional planning.
- Roche commercialized a treatment after partnering with Sarepta, while Sarepta simultaneously faced a regulatory pause in the U.S.